Literature DB >> 31135729

Maternal and Neonatal Morbidity Associated With Early Term Delivery of Large-for-Gestational-Age But Nonmacrosomic Neonates.

Morgen S Doty1, Han-Yang Chen, Baha M Sibai, Suneet P Chauhan.   

Abstract

OBJECTIVE: To evaluate whether, at 37-39 weeks of gestation, delivery of a neonate with a birth weight that is 90% or greater for gestational age but less than 4,000 g is associated with increased composite maternal and neonatal morbidity.
METHODS: This retrospective cohort study used U.S. Vital Statistics datasets for the years 2011-2013. Inclusion criteria were singleton pregnancies delivered at 37-39 weeks of gestation after labor in which the neonates were nonanomalous, and either appropriate for gestational age or large for gestational age (LGA) neonates with birth weights of less than 4,000 g (our threshold for macrosomia). The coprimary outcomes were composite maternal morbidity (any of the following: maternal transfusion, ruptured uterus, unplanned hysterectomy, admission to intensive care unit, or unplanned procedure) and composite neonatal morbidity (any of the following: Apgar score less than 5 at 5 minutes, assisted ventilation for more than 6 hours, seizure or serious neurologic dysfunction, significant birth injury or neonatal mortality). Multivariable Poisson regression models were used to calculate adjusted relative risk (aRR) and 95% CI.
RESULTS: Among the 3.9 million women who met inclusion criteria, 1.3% delivered neonates who were LGA but nonmacrosomic. The rate of composite maternal morbidity was 53% higher women who delivered nonmacrosomic LGA neonate (6.27 vs 4.09/1,000 live births; aRR 1.40, 95% CI 1.25-1.56). This increased risk of composite maternal morbidity persisted in analyses stratified by diabetes. The rate of composite neonatal morbidity was 83% higher for nonmacrosomic LGA neonates (11.09 vs 6.07/1,000 live births; aRR 1.47, 95% CI 1.35-1.60) and persisted in analyses stratified by diabetes.
CONCLUSION: At 37-39 weeks of gestation, delivery of a neonate with a birth weight that is 90% or greater for gestational age but less than 4,000 g is associated with increased composite maternal and neonatal morbidity.

Entities:  

Year:  2019        PMID: 31135729     DOI: 10.1097/AOG.0000000000003285

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  5 in total

1.  The impact of single-step and sequential embryo culture systems on obstetric and perinatal outcomes in singleton pregnancies: the Massachusetts Outcomes Study of Assisted Reproductive Technology.

Authors:  Caitlin R Sacha; Daksha Gopal; Chia-Ling Liu; Howard R Cabral; Judy E Stern; Daniela A Carusi; Catherine Racowsky; Charles L Bormann
Journal:  Fertil Steril       Date:  2022-04-23       Impact factor: 7.490

2.  First Trimester Microelements and their Relationships with Pregnancy Outcomes and Complications.

Authors:  Małgorzata Lewandowska; Barbara Więckowska; Stefan Sajdak; Jan Lubiński
Journal:  Nutrients       Date:  2020-04-16       Impact factor: 5.717

3.  Which growth standards should be used to identify large- and small-for-gestational age infants of mothers with type 1 diabetes? A pre-specified analysis of the CONCEPTT trial.

Authors:  Claire L Meek; Rosa Corcoy; Elizabeth Asztalos; Laura C Kusinski; Esther López; Denice S Feig; Helen R Murphy
Journal:  BMC Pregnancy Childbirth       Date:  2021-01-29       Impact factor: 3.007

4.  Measuring intrauterine growth in healthy pregnancies using quantitative magnetic resonance imaging.

Authors:  Ariunzaya Amgalan; Kushal Kapse; Dhineshvikram Krishnamurthy; Nicole R Andersen; Rima Izem; Ahmet Baschat; Jessica Quistorff; Alexis C Gimovsky; Homa K Ahmadzia; Catherine Limperopoulos; Nickie N Andescavage
Journal:  J Perinatol       Date:  2022-02-23       Impact factor: 3.225

Review 5.  Fetal Growth Acceleration-Current Approach to the Big Baby Issue.

Authors:  Jan Modzelewski; Anna Kajdy; Katarzyna Muzyka-Placzyńska; Dorota Sys; Michał Rabijewski
Journal:  Medicina (Kaunas)       Date:  2021-03-02       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.